VANCOUVER, BRITISH COLUMBIA, Jul 06, 2011 (MARKETWIRE via COMTEX) — Verisante Technology, Inc. CA: VRS -2.47% (otcqx:VRSEF)(pink sheets:VRSEF) (the “Company” or “Verisante”) is pleased to announce that the results of a pilot study on lung cancer detection will be published in the prestigious Journal of Thoracic Oncology in July. The results of the pilot study indicate that the Company’s system technology could set a new standard for the early detection of lung cancer.

The Company owns, co-owns, or has the exclusive rights to all of the technology used in the pilot study, which was generously funded by the Canadian Institutes of Health Research (“CIHR”) and the Canadian Cancer Society.

Verisante is currently developing a commercial prototype of the laser Raman system, the Verisante Core(TM), licensed from the BC Cancer Agency which, when combined with the ClearVu(TM) and ClearVu Elite(TM) systems recently acquired from Perceptronics Medical Inc., reduces false positives by over 75% compared to current endoscopic methods.